Breakthrough Epilepsy Treatment: LRP-661 Shows Promising Results in Pre-Clinical Trials

Introduction to LRP-661

London Research & Pharmaceuticals recently presented promising pre-clinical data for their lead compound, LRP-661, at the Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) held in Madrid. This compound, also known as Cannabidiol Sulphate (CBDS), shows significant potential for the treatment of epilepsy.

Enhanced Safety and Efficacy

LRP-661 has demonstrated superior safety and efficacy profiles across multiple species in pre-clinical studies. The compound's ability to mitigate seizures effectively, particularly in tests involving PTZ fully kindled mice and maximal electroshock seizure (MES) models, suggests it could be a robust treatment option for epilepsy patients.

Compared to currently available cannabidiol treatments, LRP-661 exhibits better gastrointestinal tolerance and lacks the liver and kidney toxicity issues present in other formulations. The drug also promises a lower risk of drug-drug interactions, highlighting its potential safety advantages.

Oral Formulation Advancements

The oral formulation of LRP-661 marks a significant step forward, making it easier for patients to incorporate into their daily routines. Unlike other cannabidiol treatments suspended in sesame oil, which can be less tolerable, LRP-661's formulation enhances its bioavailability and predictability.

Impact on Epilepsy Treatment Landscape

The introduction of LRP-661 has the potential to disrupt the current epilepsy treatment landscape, providing a safer and more effective option for patients. The pre-clinical data presented at the Eilat Conference has already garnered high praise, indicating the significance of these findings in advancing epilepsy therapy.

Focus on Rare Epileptic Syndromes

LRP is also pursuing orphan drug designation for LRP-661 in treating Dravet Syndrome and Lennox-Gastaut Syndrome. These rare conditions are urgently in need of new and effective treatments, and LRP-661's promising results provide hope for better management and improvement in patients' quality of life.

Future Clinical Studies

The company is preparing to release efficacy data in a Dravet syndrome model soon. These studies will further test LRP-661's effectiveness and contribute to the understanding of its potential impacts on this challenging disorder.

Background on LRP-661

LRP-661 is a semi-synthetic, orally available form of cannabidiol. Unlike the existing prescription cannabidiol oil solution marketed as Epidiolex®, LRP-661 offers predictable dosing and formulation, which could position it as a game-changer in epilepsy treatment.

About London Research & Pharmaceuticals

London Research & Pharmaceuticals focuses on developing highly druggable formulations to address unmet medical needs. The company is actively involved in pre-clinical research across various therapeutic areas, including inflammation, infectious diseases, oncology, and psychiatric disorders. They are also open to partnerships to further their innovative drug discovery efforts.

Conclusion

The advancements in LRP-661 underscore the commitment of London Research & Pharmaceuticals to revolutionize epilepsy treatment. Their research and development efforts are paving the way for new therapies that could significantly improve patient outcomes.

Contact Information

For more information about LRP-661 and other innovative compounds, please reach out to Dr. Mark Innamorato, Chief Strategy Officer, at mark.innamorato@londonresearch.ca, or visit their website at www.londonresearch.ca.